Chapter 16 of 25
What “targeted” means
Targeted medicines interfere with a protein or molecular process that supports cancer growth. Some are antibodies delivered by infusion; others are tablets. “Targeted” does not mean harmless, perfectly selective or certain to work. Normal tissues may share the target, and tumours can find ways around the blocked pathway.
The right question is whether a particular medicine has evidence for your cancer type and situation. Finding a gene alteration is not enough by itself. A change may be nonfunctional, may not predict drug response, or may have supporting evidence only in another cancer. A specialist molecular tumour board can help interpret unusual results.
Cetuximab and EGFR
EGFR is a growth-signalling receptor found on many head and neck squamous cancer cells. Cetuximab is an antibody against EGFR. It is used with other treatments in selected recurrent or metastatic disease and with radiation in some patients for whom a cisplatin-based approach is unsuitable. The choice depends on the precise clinical setting; routine EGFR mutation testing is not the selection method used for cetuximab in ordinary head and neck squamous cancer.
Important adverse effects include acne-like skin rash, low magnesium, infusion reactions and skin or nail problems. A rash should be assessed and treated rather than assumed to be an allergy or a reason to stop treatment independently. Breathing difficulty, faintness or swelling during an infusion need immediate staff attention. Blood tests and preventive skin care are part of the treatment plan.
Why cetuximab is not automatically a gentler equivalent
RTOG 1016 and De-ESCALaTE HPV compared radiotherapy with cetuximab against radiotherapy with cisplatin in HPV-positive oropharyngeal cancer. Cetuximab produced worse cancer-control outcomes and did not provide the hoped-for overall toxicity advantage. These trials argue against replacing cisplatin solely to reduce treatment intensity in someone who can appropriately receive cisplatin.
People who genuinely cannot receive cisplatin need an individualized discussion about radiation alone or other radiosensitizing treatments. The evidence differs between options, and their risks also differ. Kidney disease, substantial hearing impairment, frailty and other factors require a clinical assessment rather than an automatic drug swap.
Molecular targets in salivary gland cancers
Salivary cancers include many tissue types. Some salivary duct cancers express HER2 or the androgen receptor; secretory carcinomas commonly have an NTRK gene fusion. These findings can guide treatment in advanced disease, using appropriate HER2-directed therapy, androgen-directed treatment or a TRK inhibitor when the specific criteria are met. Testing should match the pathological diagnosis.
HER2 and androgen receptor can be assessed with protein-based tests, with additional methods when needed. Gene fusions may require molecular testing. A negative result on a narrow or technically limited panel does not rule out every actionable alteration. Ask what the assay measures, whether sufficient tumour was tested and whether additional testing would change the plan.
When broad sequencing is useful
Next-generation sequencing, or NGS, tests several genes at once. It is not necessary for every newly diagnosed, potentially curable head and neck squamous cancer. The immediate decisions may instead depend on pathology, site, HPV testing where indicated and PD-L1 in an appropriate setting. Ordering a broad test should not delay a time-sensitive curative treatment without a clear reason.
NGS can be useful in uncommon histologies, advanced disease with limited options, suspected actionable fusions or clinical-trial selection. Tumour testing and inherited genetic testing answer different questions. A tumour finding may occasionally prompt counselling and a separate blood or saliva test to assess an inherited risk.
Evaluating a newer treatment
Clinical trials may investigate new immune combinations, vaccines, antibodies, cell therapies, molecular drugs or radiation techniques. Ask whether an option is approved for this indication, recommended by an applicable guideline, supported by a phase III trial, or still experimental. A promising conference result does not automatically establish worldwide approval or a new standard.
The discussion should include trial visits, eligibility, costs, alternatives and the possibility of receiving a comparison treatment. Treatment availability differs between countries and centres. Avoid buying medicines online or using unregulated “personalized” treatments because a molecular report lists a theoretical target. A responsible plan connects the result to credible evidence and a realistic monitoring strategy.
References and evidence review
- Gillison et al. RTOG 1016 (2019)
- Mehanna et al. De-ESCALaTE HPV (2019)
- Geiger et al. ASCO guideline: salivary gland malignancy (2021)
- ASTRO clinical practice guideline: HPV-positive oropharyngeal cancer (2024)
Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.